These milestones position XellSmart as a global leader in advancing innovative iPSC-derived regenerative cell therapies for CNS diseases, including Parkinson's disease and ALS. Dr. Michael Lee ...

Combining pioneering iPSC technology and patented live cell bioimaging, LumiSTAR is opening up exciting new possibilities in the treatment of various diseases and the development of innovative new dru ...

Co. Ltd. has announced IND clearances by the FDA for its XS-411 and XS-228 cell therapies, for Parkinson’s disease and amyotrophic lateral sclerosis (ALS), respectively.

SUZHOU, China, April 15, 2025 /PRNewswire/ --In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted ...

This study was officially approved by China's National Health Commission, making XellSmart the first to complete an iPSC-derived cell therapy for Parkinson's disease in China. In the clinical ...